Compare Neurocrine Biosciences Inc (NBIX) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs DENTSPLY SIRONA Inc — how do they compare? Neurocrine Biosciences Inc trades at $141.09 (market cap $14.36B), while DENTSPLY SIRONA Inc trades at $8.78 (market cap $1.73B). The key difference: Neurocrine Biosciences Inc is far larger — about 8.3× DENTSPLY SIRONA Inc's market cap, and DENTSPLY SIRONA Inc pays a 5.04% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and DENTSPLY SIRONA Inc for 72 Days on average.
| NBIX | XRAY | |
|---|---|---|
Market Cap | $14.36B | $1.73B |
Volume | 1,237,180 | 6,198,582 |
Sector | Health | Health |
52-Week High | $185.50 | $14.68 |
52-Week Low | $123.10 | $8.52 |
Typical Hold Time | 23 Days | 72 Days |
Enterprise Value | $14.37B | $3.80B |
Dividend Yield | — | 5.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a 20.91% net income margin and consistent earnings beats, including a Q2 2026 EPS of $2.85 versus $1.85 expected. Recent news highlights pipeline advancements in Prader-Willi syndrome and active participation in investor conferences. Key support is at $142, with resistance at $145.
The outlook is positive, driven by robust product growth, particularly from Ingrezza and Crenessity, and a deep pipeline. Risks include pricing pressures on Ingrezza by 2029 and execution challenges in portfolio expansion. Analyst consensus is strongly bullish with a $204.18 price target, suggesting significant upside from current levels.
DENTSPLY SIRONA (XRAY) trades at $8.54, near its 52-week low, with bearish technical indicators and mixed fundamentals. The company reported Q2 2026 EPS of $0.52 beating expectations but revenue declined 4.1% year-over-year. Net income remains negative at -$598 million for 2025, though margins show slight improvement. Analyst consensus is mixed with 37.5% buy ratings but a $13.40 price target suggesting 57% upside potential from current levels.
The stock presents a high-risk turnaround opportunity with significant upside if management's restructuring efforts succeed, but faces headwinds from declining sales, margin pressure, and competitive challenges in dental markets. Institutional ownership changes and ongoing transformation investments create both uncertainty and potential for recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About DENTSPLY SIRONA Inc
Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters
Read more on XRAY →
